News headlines about BioDelivery Sciences International (NASDAQ:BDSI) have been trending somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 48.1658255523914 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- 3 Small Biotechs Turn on the Revenue Jets (realmoneypro.thestreet.com)
- BioDelivery Sciences International (BDSI) Posts Earnings Results (americanbankingnews.com)
- BioDelivery’s (BDSI) CEO Herm Cukier on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down (zacks.com)
- BioDelivery Sciences International, Inc.’s (BDSI) CEO Herm Cukier on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
Shares of BioDelivery Sciences International traded down $0.02, reaching $2.88, during midday trading on Friday, according to MarketBeat.com. 404,567 shares of the stock were exchanged, compared to its average volume of 289,636. The company has a market capitalization of $172.12 million, a P/E ratio of -7.37 and a beta of 0.38. The company has a debt-to-equity ratio of 35.82, a current ratio of 1.40 and a quick ratio of 1.13. BioDelivery Sciences International has a twelve month low of $1.70 and a twelve month high of $3.42.
A number of research analysts have weighed in on BDSI shares. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th. Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Tuesday, June 5th. ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, HC Wainwright decreased their target price on shares of BioDelivery Sciences International from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Wednesday, May 23rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. BioDelivery Sciences International has an average rating of “Buy” and an average target price of $4.13.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Further Reading: Market Capitalization in the Stock Market
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.